Altered Circulating Leptin, hGH, and IGF-I in Prediabetes and Screening-Diagnosed T2DM Unrelated to Metabolic Syndrome in Women Post Gestational Diabetes

Abstract

Recently, we proposed two pathophysiologic subtypes of type 2 diabetes mellitus (T2DM), one related and one unrelated to metabolic syndrome. To begin to understand the pathophysiology of the subtype unrelated to metabolic syndrome, we now measured selected hormones and signaling molecules in affected individuals. In this cross-sectional analysis, we examined 138 women out of the monocenter, post gestational diabetes study PPSDiab. Of these women, 73 had prediabetes or screening-diagnosed T2DM, 40 related to metabolic syndrome and 33 unrelated. The remaining 65 women were normoglycemic controls. Our analysis included medical history, anthropometrics, oral glucose tolerance testing, laboratory chemistry, and cardiopulmonary exercise testing. In addition, plasma proinsulin/insulin ratio, growth hormone (hGH) nadir during oral glucose tolerance testing, Insulin-like Growth Factor I (IGF-I), Leptin, Resistin, Adiponectin, Fetuin-a, FGF21, and myostatin were measured. Compared to controls, women with prediabetes or screening-diagnosed T2DM unrelated to metabolic syndrome depicted higher plasma Leptin [10.47(6.6–14.57) vs. 5.52(3.15–10.02); p<0.0001] and IGF-I [193.01(171.00–213.30) vs. 167.97(138.77–200.64); p=0.0008], as well as a lower hGH nadir [0.07(0.05–0.15) vs. 0.14(0.08–0.22; p<0.0001]. These differences were independent of body adiposity. Women with prediabetes or T2DM related to metabolic syndrome, in comparison to controls, displayed elevated Leptin, Fetuin-a, and FGF21, as well as reduced Adiponectin and hGH nadir. Based on our study, altered Leptin and hGH/IGF-I signaling could potentially contribute to the pathophysiology of prediabetes and T2DM unrelated to metabolic syndrome. Further mechanistic investigations of these signaling pathways in the context of lean T2DM are necessary to test causal relationships.

Key words

insulin resistance - lean risk phenotype - subclassification - insulin secretion

Publikationsverlauf

Eingereicht: 10. Februar 2022

Angenommen nach Revision: 12. Mai 2022

Accepted Manuscript online:
12. Mai 2022

Artikel online veröffentlicht:
12. Juli 2022

• References

• 1 Rottenkolber M, Gar C, Then C. et al. A pathophysiology of type 2 diabetes unrelated to metabolic syndrome. J Clin Endocrinol Metab 2021; 106: 1460-1471
• 2 Vangipurapu J, Stancakova A, Kuulasmaa T. et al. Both fasting and glucose-stimulated proinsulin levels predict hyperglycemia and incident type 2 diabetes: a population-based study of 9,396 Finnish men. PloS One 2015; 10: e0124028
• 3 Schilbach K, Gar C, Lechner A. et al. Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol 2019; 181: 55-67
• 4 Hoeck HC, Vestergaard P, Jakobsen PE. et al. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues. J Clin Endocrinol Metab 2000; 85: 1467-1472
• 5 Friedrich N, Thuesen B, Jørgensen T. et al. The association between IGF-I and insulin resistance: a general population study in Danish adults. Diabetes Care 2012; 35: 768-773
• 6 Kharitonenkov A, Shiyanova TL, Koester A. et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635
• 7 Rottenkolber M, Ferrari U, Holland L. et al. The diabetes risk phenotype of young women with recent gestational diabetes. J Clin Endocrinol Metab 2015; 100: E910-E918
• 8 Ou HY, Yang YC, Wu HT. et al. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab 2012; 97: 4717-4723
• 9 Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metab Clin Exp 2015; 64: 13-23
• 10 Zuo H, Shi Z, Yuan B. et al. Association between serum leptin concentrations and insulin resistance: a population-based study from China. PLoS One 2013; 8: e54615
• 11 Moonishaa T, Nanda S, Shamraj M. et al. Evaluation of leptin as a marker of insulin resistance in type 2 diabetes mellitus. Int J Appl Basic Med Res 2017; 7: 176-180
• 12 Steppan CM, Bailey ST, Bhat S. et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312
• 13 Li S, Shin HJ, Ding EL. et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302: 179-188
• 14 Yamauchi T, Iwabu M, Okada-Iwabu M. et al. Adiponectin receptors: a review of their structure, function and how they work. Best Pract Res Clin Endocrinol Metab 2014; 28: 15-23
• 15 Gar C, Rottenkolber M, Grallert H. et al. Physical fitness and plasma leptin in women with recent gestational diabetes. PLoS One 2017; 12: e0179128
• 16 Brandt C, Nielsen AR, Fischer CP. et al. Plasma and muscle myostatin in relation to type 2 diabetes. PLoS One 2012; 7: e37236
• 17 [Anonymous] Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
• 18 [Anonymous] 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 2020; 43: S14-S31
• 19 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
• 20 Kahn SE, Prigeon RL, McCulloch DK. et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672
• 21 Chen C, Cheung BM, Tso AW. et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34: 2113-2115
• 22 Bobbert T, Schwarz F, Fischer-Rosinsky A. et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36: 145-149
• 23 Stefan N, Fritsche A, Weikert C. et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57: 2762-2767
• 24 Liu W, Zhou X, Li Y. et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: a population-based study. Medicine (Baltimore) 2020; 99: e19052
• 25 Gar C, Rottenkolber M, Haenelt M. et al. Altered metabolic and hormonal responses to moderate exercise in overweight/obesity. Metabolism 2020; 107: 154219
• 26 Aguirre GA, De Ita JR, de la Garza RG. et al. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med 2016; 14: 3
• 27 Wang LK, Wang H, Wu XL. et al. Relationships among resistin, adiponectin, and leptin and microvascular complications in patients with type 2 diabetes mellitus. J Int Med Res 2020; 48: 300060519870407
• 28 Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T. et al. Role of Leptin in Inflammation and Vice Versa. Int J Mol Sci 2020; 21: 5887
• 29 Gahete MD, Cordoba-Chacon J, Lin Q. et al. Insulin and IGF-I inhibit GH synthesis and release in vitro and in vivo by separate mechanisms. Endocrinology 2013; 154: 2410-2420
• 30 Larsson SC, Michaëlsson K, Burgess S. IGF-1 and cardiometabolic diseases: a Mendelian randomisation study. Diabetologia 2020; 63: 1775-1782
• 31 Sinnott-Armstrong N, Tanigawa Y, Amar D. et al. Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet 2021; 53: 185-194
• 32 Cao LH, Lu FM, Lu XJ. et al. Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. J Cell Biochem 2018; 119: 9513-9518